The field of organs-on-chips scored an early victory Tuesday: Boston organ-on-a-chip startup Emulate has partnered with the Food and Drug Administration to test whether the technology works for toxicity screening purposes.

But this is just an early gambit into the wider world of organs-on-chips — since tox screening accounts for just 10 percent of the preclinical testing typically conducted on animals, said Dr. Thomas Hartung, who is director of the Center for Alternatives to Animal Testing at Johns Hopkins University.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Complete metabolic profile and other laboratory test in real-time not drawing blood or urine through the integment…

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy